Literature DB >> 18192961

Loperamide: a pharmacological review.

Daniel E Baker1.   

Abstract

Loperamide is an antidiarrheal medication approved for the control of diarrhea symptoms and is available without a prescription. Loperamide works by a number of different mechanisms of action that decrease peristalsis and fluid secretion, resulting in longer gastrointestinal transit time and increased absorption of fluids and electrolytes from the gastrointestinal tract. It is a phenylpiperidine derivative with a chemical structure similar to opiate receptor agonists such as diphenoxylate and haloperidol. It was designed to maintain the antidiarrheal activity of these drugs, but minimize the negative aspects associated with their effects on the opiate receptor. Because of loperamides's low oral absorption and inability to cross the blood-brain barrier, it has minimal central nervous system effects. It also has a longer duration of action than diphenoxylate. However, it has no clinically significant analgesic activity and does not decrease the pain associated with some forms of irritable bowel syndrome and diarrhea. Loperamide is metabolized by the cytochrome P450 (CYP) system and is a substrate for the CYP3A4 isoenzyme. Concurrent administration with CYP3A4 inhibitors may elevate loperamide concentrations. Common adverse reactions to loperamide include cramps and nausea. Loperamide is an effective treatment for patients with painless diarrhea and is considered to be free of abuse potential.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18192961

Source DB:  PubMed          Journal:  Rev Gastroenterol Disord        ISSN: 1533-001X


  37 in total

1.  Discovery and Characterization of the Biflavones From Ginkgo biloba as Highly Specific and Potent Inhibitors Against Human Carboxylesterase 2.

Authors:  Yun-Qing Song; Rong-Jing He; Dan Pu; Xiao-Qing Guan; Jin-Hui Shi; Yao-Guang Li; Jie Hou; Shou-Ning Jia; Wei-Wei Qin; Sheng-Quan Fang; Guang-Bo Ge
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.810

2.  Loperamide dependence and abuse.

Authors:  Ryan MacDonald; Jason Heiner; Joshua Villarreal; Jared Strote
Journal:  BMJ Case Rep       Date:  2015-05-02

3.  Loperamide therapy for voluminous diarrhea in Ebola virus disease.

Authors:  Daniel S Chertow; Timothy M Uyeki; Herbert L DuPont
Journal:  J Infect Dis       Date:  2015-01-08       Impact factor: 5.226

Review 4.  Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.

Authors:  Michael S Toce; Peter R Chai; Michele M Burns; Edward W Boyer
Journal:  J Med Toxicol       Date:  2018-10-30

Review 5.  HIV, opiates, and enteric neuron dysfunction.

Authors:  J J Galligan
Journal:  Neurogastroenterol Motil       Date:  2015-04       Impact factor: 3.598

6.  Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers.

Authors:  Tae-Eun Kim; Howard Lee; Kyoung Soo Lim; SeungHwan Lee; Seo-Hyun Yoon; Kyung-Mi Park; Hyesun Han; Sang-Goo Shin; In-Jin Jang; Kyung-Sang Yu; Joo-Youn Cho
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

Review 7.  Loperamide cardiotoxicity: "A Brief Review".

Authors:  Tamer Akel; Soad Bekheit
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-11-10       Impact factor: 1.468

8.  Lubeluzole: from anti-ischemic drug to preclinical antidiarrheal studies.

Authors:  Maria Maddalena Cavalluzzi; Roberta Budriesi; Maria Antonietta De Salvia; Laura Quintieri; Monica Piarulli; Gualtiero Milani; Roberta Gualdani; Matteo Micucci; Ivan Corazza; Antonio Rosato; Maurizio Viale; Leonardo Caputo; Carlo Franchini; Giovanni Lentini
Journal:  Pharmacol Rep       Date:  2020-10-19       Impact factor: 3.024

Review 9.  New treatments for irritable bowel syndrome in women.

Authors:  Mopelola A Adeyemo; Lin Chang
Journal:  Womens Health (Lond)       Date:  2008-11

10.  Priapism induced by boceprevir-CYP3A4 inhibition and α-adrenergic blockade: case report.

Authors:  Kyle P Hammond; Craig Nielsen; Sunny A Linnebur; Jacob A Langness; Graham Ray; Paul Maroni; Jennifer J Kiser
Journal:  Clin Infect Dis       Date:  2013-10-02       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.